Skip to main content
Fig. 1 | Virology Journal

Fig. 1

From: Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

Fig. 1

TMC647055HPC2001 study design. aRibavirin given BID at doses of 1000–1200 mg. bPanel 4 Arm 1 included 1 GT1c- and 1 GT1l-infected patient, based on NS5B-based geno/subtyping. Follow-up therapy with pegIFN + RBV was based on on-treatment response and was initiated only if: week 4 HCV RNA ≥25 IU/mL (Panels 1–3: 36 weeks of follow-up therapy); week 4 HCV RNA <25 IU/mL detectable or HCV RNA confirmed detectable between week 4 and week 11 (Panels 1–2: 12 weeks of follow-up therapy). BID: twice daily; GT: genotype; pegIFN: pegylated interferon; QD: once daily; RBV: ribavirin; RTV: ritonavir; SMV: simeprevir; SVR12: sustained virologic response 12 weeks after actual end of treatment

Back to article page

Virology Journal

ISSN: 1743-422X